Global specialty ingredients solution provider Barentz International recently announced the acquisition of Anshul Life Sciences in India, a specialty chemicals distributor that caters to regulated pharmaceuticals, food & nutraceuticals, and personal care markets.
With this acquisition, Barentz establishes a life science distribution platform in India. It is expected to open a realm of strategic opportunities for growth across the country and the broader Asia Pacific region. Both companies are committed to ensuring a seamless transition and maintaining the highest standards of value-added services. Nagarajan Kailasam (CEO, Anshul Life Sciences) and the current team of Anshul Life Sciences will continue to manage the day-to-day business operations.
“We are extremely excited to welcome Anshul Life Sciences to the Barentz Group,” commented Marc Duchene, CEO APAC. “The acquisition underpins our ambitions to further grow in India, one of our key strategic markets, and the Asia Pacific region in general. The acquisition benefits our customers and principals by providing access to a broader portfolio of high-quality pharmaceuticals excipients and products and a deeper pool of expertise. We are delighted that Mr. Nagarajan will continue to lead the business. Together, we aim to enhance our offering and better serve the needs of the dynamic Indian market and beyond.”
“Barentz aligns strongly with the entrepreneurial spirit and ethical standards of Anshul Life Science’s founding partners,” added Nagarajan Kailasam, CEO of Anshul Life Sciences. “We are excited to join the Barentz family and start our collaboration to capture the enormous potential of the Indian market by offering even more comprehensive solutions to our customers and principals in the Indian market and beyond. We are looking forward to the future and the growing international reach that this strategic move will bring to Anshul Life Sciences.”
Source: chemanager-online.com
Abbott has announced plans to separate its Nutrition business into an independent, publicly traded company by the end of next year. The Nutrition company will have approximately $8.5 billion in annual sales, with around 16,000 employees and 14 manufacturing sites around the globe.
Merck has entered into a definitive agreement to acquire biotech company Silence Therapeutics, focused on siRNA-therapies in areas of high unmet need. The purchase price represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion.
The development will introduce a new generation of insulin production to one of the company’s largest integrated research and manufacturing sites and strengthen long-term supply for millions of people living with diabetes worldwide.
